vs

Side-by-side financial comparison of FIRST COMMUNITY CORP (FCCO) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

FIRST COMMUNITY CORP is the larger business by last-quarter revenue ($23.2M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). FIRST COMMUNITY CORP runs the higher net margin — 23.7% vs -1398.3%, a 1422.1% gap on every dollar of revenue. Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 19.1%).

United Community is an American bank. United is one of the largest full-service financial institutions in the Southeast, with $27.7 billion in assets and 200 offices in Alabama, Florida, Georgia, North Carolina, South Carolina and Tennessee. In addition to its presence in the Southeast, United Community is the largest bank headquartered in South Carolina by total asset size.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FCCO vs RNA — Head-to-Head

Bigger by revenue
FCCO
FCCO
1.9× larger
FCCO
$23.2M
$12.5M
RNA
Higher net margin
FCCO
FCCO
1422.1% more per $
FCCO
23.7%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
19.1%
FCCO

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
FCCO
FCCO
RNA
RNA
Revenue
$23.2M
$12.5M
Net Profit
$5.5M
$-174.4M
Gross Margin
Operating Margin
-1513.5%
Net Margin
23.7%
-1398.3%
Revenue YoY
434.0%
Net Profit YoY
37.6%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FCCO
FCCO
RNA
RNA
Q1 26
$23.2M
Q4 25
$20.6M
Q3 25
$20.5M
$12.5M
Q2 25
$19.5M
$3.8M
Q1 25
$18.4M
$1.6M
Q4 24
$17.5M
$3.0M
Q3 24
$17.0M
$2.3M
Q2 24
$16.3M
$2.0M
Net Profit
FCCO
FCCO
RNA
RNA
Q1 26
$5.5M
Q4 25
Q3 25
$5.2M
$-174.4M
Q2 25
$5.2M
$-157.3M
Q1 25
$4.0M
$-115.8M
Q4 24
$-102.3M
Q3 24
$3.9M
$-80.4M
Q2 24
$3.3M
$-70.8M
Operating Margin
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
Q3 25
32.2%
-1513.5%
Q2 25
34.2%
-4448.7%
Q1 25
28.2%
-8360.9%
Q4 24
30.9%
-4069.6%
Q3 24
29.5%
-4200.9%
Q2 24
24.7%
-4040.4%
Net Margin
FCCO
FCCO
RNA
RNA
Q1 26
23.7%
Q4 25
Q3 25
25.4%
-1398.3%
Q2 25
26.6%
-4089.3%
Q1 25
21.8%
-7360.0%
Q4 24
-3439.5%
Q3 24
22.7%
-3441.7%
Q2 24
20.0%
-3461.8%
EPS (diluted)
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
$0.62
Q3 25
$0.67
$-1.27
Q2 25
$0.67
$-1.21
Q1 25
$0.51
$-0.90
Q4 24
$0.55
$-0.80
Q3 24
$0.50
$-0.65
Q2 24
$0.42
$-0.65

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FCCO
FCCO
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$220.8M
$1.9B
Total Assets
$2.4B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Stockholders' Equity
FCCO
FCCO
RNA
RNA
Q1 26
$220.8M
Q4 25
$167.6M
Q3 25
$161.6M
$1.9B
Q2 25
$155.5M
$1.2B
Q1 25
$150.0M
$1.3B
Q4 24
$144.5M
$1.4B
Q3 24
$143.3M
$1.5B
Q2 24
$136.2M
$1.2B
Total Assets
FCCO
FCCO
RNA
RNA
Q1 26
$2.4B
Q4 25
$2.1B
Q3 25
$2.1B
$2.1B
Q2 25
$2.0B
$1.4B
Q1 25
$2.0B
$1.5B
Q4 24
$2.0B
$1.6B
Q3 24
$1.9B
$1.6B
Q2 24
$1.9B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FCCO
FCCO
RNA
RNA
Operating Cash FlowLast quarter
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
$18.7M
Q3 25
$9.2M
$-156.2M
Q2 25
$-236.0K
$-199.7M
Q1 25
$6.4M
$-124.8M
Q4 24
$11.6M
$-99.9M
Q3 24
$10.8M
$-65.6M
Q2 24
$-292.0K
$-65.0M
Free Cash Flow
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
$17.6M
Q3 25
$9.0M
$-156.9M
Q2 25
$-454.0K
$-203.0M
Q1 25
$6.2M
$-128.6M
Q4 24
$10.5M
$-103.8M
Q3 24
$10.6M
$-67.3M
Q2 24
$-634.0K
$-65.5M
FCF Margin
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
85.3%
Q3 25
44.2%
-1257.6%
Q2 25
-2.3%
-5277.1%
Q1 25
34.0%
-8174.3%
Q4 24
60.3%
-3491.0%
Q3 24
62.5%
-2881.8%
Q2 24
-3.9%
-3204.6%
Capex Intensity
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
5.4%
Q3 25
0.6%
5.7%
Q2 25
1.1%
86.9%
Q1 25
1.1%
238.6%
Q4 24
6.3%
131.7%
Q3 24
1.1%
72.9%
Q2 24
2.1%
26.0%
Cash Conversion
FCCO
FCCO
RNA
RNA
Q1 26
Q4 25
Q3 25
1.77×
Q2 25
-0.05×
Q1 25
1.61×
Q4 24
Q3 24
2.80×
Q2 24
-0.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FCCO
FCCO

Net Interest Income$18.4M79%
Noninterest Income$4.8M21%

RNA
RNA

Segment breakdown not available.

Related Comparisons